You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ovarian Tumors with PARP Resistance

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignant Tumor of Breast, Malignant Tumors of Digestive Organs, Malignant Tumors of Female Genital Organs Trial in Houston

Recruiting
  • Malignant Neoplasm of Breast
  • +4 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 29, 2021

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 12, 2023

Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

Not yet recruiting
  • Breast Cancer
  • +7 more
  • (no location specified)
Sep 26, 2023

Ovarian Cancer, Breast Cancer, Solid Tumor Trial in Houston, Brisbane (CYH33)

Recruiting
  • Ovarian Cancer
  • +4 more
  • New Haven, Connecticut
  • +6 more
Oct 10, 2022

Advanced Malignant Solid Tumor, Advanced Ovarian Carcinoma, Metastatic Malignant Solid Tumor Trial (BET Bromodomain Inhibitor

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +7 more
  • Atlanta, Georgia
  • +2 more
Nov 3, 2022

Advanced Pancreatic Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 Trial in

Recruiting
  • Advanced Pancreatic Carcinoma
  • +27 more
  • Gainesville, Florida
  • +3 more
Jan 3, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Toronto (Niraparib, Dostarlimab, Bevacizumab)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
May 2, 2022

HRD and Resistance to PAPPi in EOC Patients

Recruiting
  • Epithelial Ovarian Cancer
  • +6 more
  • Testing of homologous recombination deficiency
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Metastatic Malignant Solid Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in United States

Active, not recruiting
  • Metastatic Malignant Solid Neoplasm
  • +4 more
  • Laboratory Biomarker Analysis
  • +4 more
  • Phoenix, Arizona
  • +14 more
Sep 1, 2022

Solid Tumor, Extensive-stage Small-cell Lung Cancer, Locally Advanced Breast Cancer Trial in Czechia, Poland (RP12146)

Recruiting
  • Solid Tumor
  • +6 more
  • HoĊ™ovice, Czechia
  • +5 more
Jun 8, 2022

Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor Trial

Active, not recruiting
  • Fallopian Tube Endometrioid Tumor
  • +13 more
  • Orange, California
  • +19 more
Jan 10, 2023

Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer Trial run by the NCI (BMN 673)

Completed
Has Results
  • Advanced Ovarian Cancer
  • +3 more
  • BMN 673
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Feb 2, 2021

Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma Trial (Biopsy, Biospecimen Collection, Bone Marrow Aspiration and

Not yet recruiting
  • Recurrent Endometrial Carcinoma
  • Recurrent Ovarian Carcinoma
  • Biopsy
  • +5 more
  • (no location specified)
Sep 29, 2022

Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or

Recruiting
  • Ovarian Cancer
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Jul 13, 2022

    Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer Trial (Niraparib, Dostarlimab)

    Not yet recruiting
    • Recurrent Ovarian Cancer
    • +2 more
    • (no location specified)
    Jul 26, 2022

    Cytotoxic Chemotherapy and PARP Inhibition on Genomic Contexture

    Recruiting
    • Ovarian Cancer
      • Athens, Greece
        Adamantia Nikolaidi
      Aug 9, 2022

      Efficacy and Safety Trial in Zhejiang (Arsenic trioxide Tablet +Fuzuloparib Capsules)

      Recruiting
      • Efficacy and Safety
      • Arsenic trioxide Tablet +Fuzuloparib Capsules
      • Zhejiang, Hangzhou, China
        Women's Hospital School Of Medicine Zhejiang University
      Jan 23, 2022

      EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)

      Recruiting
      • EGFR-Mutated Non-Small-Cell Lung Carcinoma
      • Small Cell/Neuroendocrine
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 20, 2023

      Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or

      Completed
      • Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
      • Avelumab Phase 1b
      • +3 more
      • Fayetteville, Arkansas
      • +57 more
      Jan 18, 2023

      Ovarian Cancer Trial in Chongqing (fluzopanib and bevacizumab)

      Recruiting
      • Ovarian Cancer
      • fluzopanib and bevacizumab
      • Chongqing, Chongqing, China
        Chongqing Cancer Hospital
      Sep 19, 2022

      Ovarian Cancer Trial (JPI-547)

      Not yet recruiting
      • Ovarian Cancer
      • (no location specified)
      Jul 24, 2022

      Ovarian Cancer Recurrent Trial in Sutton, London (Niraparib oral capsule, SBRT)

      Not yet recruiting
      • Ovarian Cancer Recurrent
      • Niraparib oral capsule
      • SBRT
      • Sutton, Surrey, United Kingdom
      • +1 more
      Aug 10, 2023

      Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal

      Recruiting
      • Platinum-Refractory Fallopian Tube Carcinoma
      • +11 more
      • Copanlisib Hydrochloride
      • +4 more
      • Aurora, Colorado
      • +2 more
      Dec 8, 2022

      Ovarian Cancer Trial in Toronto (Cediranib, Olaparib)

      Completed
      • Ovarian Cancer
      • Toronto, Ontario, Canada
        Princess Margaret Cancer Centre
      May 3, 2022

      Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer Trial (AsiDNA, Olaparib)

      Not yet recruiting
      • Metastatic Castration-resistant Prostate Cancer
      • +2 more
      • (no location specified)
      Jan 17, 2023